Rubicon Research Limited (RUBICON) — Financial Results | 19 August 2026

Investor Takeaways

• Revenue grew 51% YoY to ₹534 crores in Q1 FY27
• PAT increased 95% YoY to ₹85 crores
• EBITDA margin expanded to 24.2% from 22.4% YoY
• R&D spend reached ₹580 crores (10.9% of revenue)
• Net working capital days declined to 114 from 126
• US facility acquired for $2.9 million
• R&D investment planned at ₹500 crores over FY26-FY28
• EBITDA margin guidance revised to 23%

Overall Tone: Positive

Key Financial Highlights

What Changed

Rubicon Research reported strong top-line growth of 51% YoY to ₹534 crores in Q1 FY27, driven by margin accretion post-Arinna acquisition and gross margin expansion to 67.7%. Operating EBITDA margin improved to 24.2% from 22.4% YoY, reflecting operational efficiencies and scale benefits. Net working capital days declined to 114 from 126, indicating improved cash flow management. R&D expenditure rose significantly to ₹580 crores (10.9% of revenue), up from ₹355 crores last year, supporting a 5.5x productivity multiple. The company finalized the acquisition of a US facility in East Brunswick, New Jersey, for approximately $2.9 million, targeting margin accretion and supply chain diversification. Management revised EBITDA margin guidance to 23% and plans phased margin expansion through capacity utilization at the Pithampur site (6 acres utilized of 30-acre campus). Gross margin improved sequentially by 140 bps, and R&D spend reached ₹60 crores per quarter, aligning with the ₹500 crores investment plan over FY26-FY28. The exit from lower-margin US businesses is underway to capture higher-margin opportunities.

Peer Comparison

Rubicon Research's valuation metrics are not directly comparable to peers due to lack of disclosed P/E, ROE, and ROCE. However, its market capitalization of ₹15,864.53 Cr is significantly lower than Sun Pharma (₹4,50,643.09 Cr) and Divi's Laboratories (₹1,79,470.03 Cr), suggesting a smaller scale relative to established peers.

Risks & Concerns

• No specific risks identified in this filing
• R&D spend increased significantly to ₹580 crores (10.9% of revenue), which may pressure near-term profitability if productivity gains do not materialize
• Integration risks associated with US facility acquisition and exit from lower-margin US businesses
• Gross margin improvement driven by sequential gains, but sustainability depends on continued capacity utilization and pricing power

Quarterly Trend